Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis

Review Gastroenterology & Hepatology

Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review

Lucas Guillo et al.

Summary: Ustekinumab has shown effectiveness in treating EIMs, especially for dermatological and rheumatological manifestations, but more data are needed to confirm its role in this setting.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management

Gerhard Rogler et al.

Summary: Inflammatory bowel diseases (IBDs) are systemic diseases that can affect not only the gut but also other organs, impacting the quality of life for patients. Understanding the prevalence, pathophysiology, and clinical presentation of extraintestinal manifestations (EIMs) is crucial for effective IBD treatment. EIMs commonly affect joints, skin, or eyes, but may also involve other organs.

GASTROENTEROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Dermatological Manifestations in Inflammatory Bowel Diseases

Elisabetta Antonelli et al.

Summary: This review summarizes the dermatologic manifestations occurring in patients with inflammatory bowel diseases, including specific manifestations, cutaneous disorders associated with IBDs, reactive mucocutaneous manifestations of IBDs, mucocutaneous conditions secondary to treatment, and manifestations due to nutritional malabsorption. An accurate dermatological examination is crucial in all IBD patients, especially in candidates to biologic therapies where drug-induced cutaneous reactions may be clinically relevant.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies

Neeraj Narula et al.

Summary: This post hoc analysis of the UNITI studies found that ustekinumab did not significantly improve overall extraintestinal manifestations of Crohn's disease compared to placebo-treated patients at weeks 6 and 52.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)

Add to Collection

Article Gastroenterology & Hepatology